Patheon, by Thermo Fisher Scientific, is a leading drug Contract Development & Manufacturing Organization (CDMO) serving more than 400 pharmaceutical clients worldwide.
Location: Dominican Republic, Distrito Nacional, Santo Domingo
Investors 1
| Date | Name | Website |
| - | Advent-Mor... | adventmorr... |
Mentions in press and media 12
| Date | Title | Description |
| 16.01.2025 | Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus | Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus By Patrick WingroveJanuary 16, 20257:24 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link A general view of the... |
| 25.07.2024 | Syngene Q1 net profit down 19% to ₹75.7 crore | Syngene International Limited, the contract research unit of Biocon, has reported a dip of 19 per cent year-on-year (Y-o-Y) in profit after tax (PAT) from ₹93.4 crore to ₹75.7 crore in the first quarter that ended June 30, 2024. Also read: ... |
| 06.03.2024 | Liquified Agency expands to South Florida as full-service ad agency. | Liquified Agency, formerly Liquified Creative, an award-winning full-service independent advertising agency, recently announced the launch of their official company rebrand, including an evolved moniker, brand identity, and enhanced website... |
| 15.05.2017 | Term Sheet — Monday, May 15 | A THOROUGH GENTLEMAN The strange story of Nin Ventures took a confusing twist on Friday night. Paid Content Securing the enterprise without boundaries From ExtraHop The announcement of his appointment came from a press release, which includ... |
| 17.02.2012 | Contract drug manufacturer Patheon names former BCRX executive new CFO | Grant comes to Patheon as the company adjusts its business strategy. Last year, the company announced a new corporate strategy that would evaluate its global footprint and cut costs. Those changes included closing some facilities. Meanwhile... |
| 11.01.2012 | CRO AAIPharma hires Patheon executive to be new CFO | “(Evans’) familiarity with our clients’ contract pharmaceutical manufacturing and development needs will help AAIPharma continue to execute our market expansion strategy and capitalize on compelling industry growth trends,” AAIPharma CEO Pa... |
| 21.12.2011 | Pozen strikes manufacturing pact with Patheon for heart drug | Pozen has said that it wants to find a partner to help commercialize PA32450. The company has brought two other products to market in partnership with large pharmaceutical companies. Migraine headache treatment Treximet is marketed by Glaxo... |
| 20.10.2011 | Patheon inks $18M deal with Boehringer on diabetes drugs in R&D | “I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules,” Patheon President of Pharmaceutical Development Services and Chief Sci... |
| - | Contract drug manufacturer Patheon names former BCRX executive new CFO | Contract drug manufacturer Patheon (TSX:PTI) has a new chief financial officer, one who is no stranger to North Carolina’s Research Triangle. Stuart Grant was named executive vice president, CFO by the Research Triangle Park-based company. ... |
| - | Patheon inks $18M deal with Boehringer on diabetes drugs in R&D | Contract drug manufacturer Patheon (TSX:PTI) has won two contracts valued at $18 million to make experimental type 2 diabetes drugs for German pharmaceutical company Boehringer Ingelheim. Research Triangle Park, North Carolina-based Patheon... |
Show more